Literature DB >> 17115951

Pandemic influenza: clinical issues.

Mark Boyd1, Kate Clezy, Richard Lindley, Rod Pearce.   

Abstract

Influenza is an acute febrile illness caused by influenza A or B viruses. It occurs mainly in winter in temperate climates, and throughout the year in tropical Australia. It is highly contagious and of considerable public health concern because of the rapidity with which epidemics evolve and the associated morbidity and mortality. Most influenza illnesses resolve over about 1 week without specific medical intervention. People at particular risk for complicated infection are those > 65 or < 5 years old, those with chronic medical comorbidities, residents of chronic care facilities (including nursing homes), and women in the second or third trimester of pregnancy. Complicated influenza infection most commonly manifests as primary viral pneumonia, combined viral and bacterial pneumonia, and secondary bacterial pneumonia. Rare but serious complications of influenza include central nervous system involvement (eg, encephalitis, transverse myelitis, aseptic meningitis, and Guillain-Barré syndrome). The recent emergence of avian influenza A/H5N1 and confirmation of sporadic cases of human H5N1 infection have heightened concern about an impending human influenza pandemic, either from a human form of H5N1 or a primary new human influenza strain. H5N1 infection in humans has been associated with severe illness and a > 50% mortality rate, with high mortality in people aged 10-39 years.

Entities:  

Mesh:

Year:  2006        PMID: 17115951     DOI: 10.5694/j.1326-5377.2006.tb00706.x

Source DB:  PubMed          Journal:  Med J Aust        ISSN: 0025-729X            Impact factor:   7.738


  12 in total

1.  Currents in contemporary ethics. Should health care providers get treatment priority in an influenza pandemic?

Authors:  Mark A Rothstein
Journal:  J Law Med Ethics       Date:  2010       Impact factor: 1.718

Review 2.  Bench-to-bedside review: bacterial pneumonia with influenza - pathogenesis and clinical implications.

Authors:  Koenraad F van der Sluijs; Tom van der Poll; René Lutter; Nicole P Juffermans; Marcus J Schultz
Journal:  Crit Care       Date:  2010-04-19       Impact factor: 9.097

3.  Injectable peramivir mitigates disease and promotes survival in ferrets and mice infected with the highly virulent influenza virus, A/Vietnam/1203/04 (H5N1).

Authors:  Nadezhda E Yun; Nathaniel S Linde; Michele A Zacks; Ian G Barr; Aeron C Hurt; Jeanon N Smith; Natallia Dziuba; Michael R Holbrook; Lifang Zhang; John M Kilpatrick; C Shane Arnold; Slobodan Paessler
Journal:  Virology       Date:  2008-01-29       Impact factor: 3.616

4.  Oral administration of Lactobacillus gasseri SBT2055 is effective for preventing influenza in mice.

Authors:  Yosuke Nakayama; Tomohiro Moriya; Fumihiko Sakai; Noriko Ikeda; Takuya Shiozaki; Tomohiro Hosoya; Hisako Nakagawa; Tadaaki Miyazaki
Journal:  Sci Rep       Date:  2014-04-10       Impact factor: 4.379

5.  Designing and screening of universal drug from neem (Azadirachta indica) and standard drug chemicals against influenza virus nucleoprotein.

Authors:  Aftab Ahmad; Muhammad Rizwan Javed; Abdul Qayyum Rao; Tayyab Husnain
Journal:  BMC Complement Altern Med       Date:  2016-12-16       Impact factor: 3.659

6.  Oral administration of heat-killed Lactobacillus kunkeei YB38 improves murine influenza pneumonia by enhancing IgA production.

Authors:  Takashi Asama; Takayuki Uematsu; Noritada Kobayashi; Tomoki Tatefuji; Ken Hashimoto
Journal:  Biosci Microbiota Food Health       Date:  2016-10-15

7.  Approaches and perspectives for online learning during the COVID-19 pandemic and future chaos.

Authors:  Shagufta Nesar; Kiran Rafiq; Muhammad Rizwan; Syed Mehmood Hasan
Journal:  J Educ Health Promot       Date:  2021-05-20

8.  β-Glucan derived from Aureobasidium pullulans is effective for the prevention of influenza in mice.

Authors:  Daisuke Muramatsu; Atsushi Iwai; Shiho Aoki; Hirohumi Uchiyama; Koji Kawata; Yosuke Nakayama; Yasuhiro Nikawa; Kisato Kusano; Mitsuyasu Okabe; Tadaaki Miyazaki
Journal:  PLoS One       Date:  2012-07-23       Impact factor: 3.240

9.  Molecular docking based screening of neem-derived compounds with the NS1 protein of Influenza virus.

Authors:  Aftab Ahmad; Ammara Ahad; Abdul Qayyum Rao; Tayyab Husnain
Journal:  Bioinformation       Date:  2015-07-31

Review 10.  Viral infection of the lung: host response and sequelae.

Authors:  Jae-Kwang Yoo; Taeg S Kim; Matthew M Hufford; Thomas J Braciale
Journal:  J Allergy Clin Immunol       Date:  2013-08-01       Impact factor: 10.793

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.